DGAP-News: Biotest AG / Key word(s): Miscellaneous
13.03.2018 / 07:00
The issuer is solely responsible for the content of this announcement.
Biotest supports a large international registry study to record data on use of Pentaglobin(R) in patients with severe bacterial infections
– High medical need due to high mortality and large patient population
– Aim of this registry is to record the use of Pentaglobin(R) under real life conditions
– Results will provide data to optimize treatment strategies with Pentaglobin(R)
– Up to 400 adult patients will be included in the multi-centric international registry
Dreieich, 13 March 2018. Biotest AG today announced that the first patient has been enrolled into the PERFORM (Pentaglobin(R)Registry For Outcome Report and Monitoring) registry – a non-interventional study assessing the efficacy and safety of Pentaglobin(R) in critically ill adult patients with severe bacterial infections or sepsis. Biotest supports the PERFORM registry, which is conducted by the University Hospital Jena, Center for Clinical Trials, as a scientifically driven study.
Sepsis is one of the leading causes of death in intensive care units and affects millions of people around the globe every year. Despite the development of new antibiotics, sepsis continues to lead to death in at least one in four patients and supportive treatment options are needed. Pentaglobin(R) is used as adjunctive therapy for severe bacterial infections and has shown to be effective in reducing mortality of patients with sepsis, severe sepsis and septic shock. The aim of this registry is to record the use of Pentaglobin(R) under real life conditions and the results we guide optimal treatment strategies.
“We are pleased to enroll the first patient in the PERFORM registry” said Prof. Frank Brunkhorst from Jena University Hospital, Center for Clinical Studies “this will further our understanding of the efficacy of Pentaglobin(R) in adult patients with severe bacterial infections and optimize the quality of its therapeutic application”.
About the PERFORM registry
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
13.03.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||0 61 03 – 8 01-0|
|Fax:||0 61 03 – 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|